Bernard Majoie
President @ Fournier-Majoie
Brussels, Belgium
Bernard Majoie is a seed investor at Fournier-Majoie in Brussels focused on Biotechnology and Medical. Bernard Majoie - President @ Fournier-Majoie
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Bernard Majoie invests in
Stages Bernard Majoie invests in
Countries Bernard Majoie invests in
Round sizes
Round size
- Seed
- $1.3M–$2.7M
Investment Focus
Industry
- Biotechnology 3 (50%)
- Medical 2 (33%)
- Health Care 1 (17%)
- Life Science 1 (17%)
- Neuroscience 1 (17%)
Stage
- Seed 2 (33%)
- Pre-Seed 1 (17%)
- Series A 1 (17%)
- Series B 1 (17%)
Country
- France 2 (33%)
- Belgium 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AgenT
|
AgenT develops the first blood diagnosis to detect Alzheimer's years before the onset of the irreversible symptoms. | $2.7M / Seed / Jul 01, 2021 | |
PEP-Therapy
|
PEP-Therapy is a biotechnology company developing first-in-class peptides as targeted therapies for severe diseases, with an initial focus on cancer. PEP-Therapy develops Cell Penetrating and Interfering Peptides (CP&IP) for the intracellular delivery of targeted therapies. These active compounds penetrate cells and block relevantintracellular protein-protein interactions, thus inhibiting key pathological mechanisms. | $3.3M / Series A / Apr 22, 2021 | |
|
AgenT
|
AgenT develops the first blood diagnosis to detect Alzheimer's years before the onset of the irreversible symptoms. | $1.2M / Pre-Seed / Jan 31, 2020 | |
reMYND
|
Their Contract Research Organization (CRO) helps their clients assess the effects of their experimental Alzheimer treatments in their proprietary mouse models.They serve the majority of the Top 10 pharmaco’s worldwide with clients in the US, Europe and Japan. They have provided pivotal in-vivo proof-of-concept data for several candidate drugscurrently in clinical development, and work actively together with Dr. Sugimoto, the inventor of Aricept. | $13.2M / Series B / Dec 18, 2018 | |
|
PEP-Therapy
|
PEP-Therapy is a biotechnology company developing first-in-class peptides as targeted therapies for severe diseases, with an initial focus on cancer. PEP-Therapy develops Cell Penetrating and Interfering Peptides (CP&IP) for the intracellular delivery of targeted therapies. These active compounds penetrate cells and block relevantintracellular protein-protein interactions, thus inhibiting key pathological mechanisms. | $1.3M / Seed / Nov 16, 2017 | |
|
PEP-Therapy
|
PEP-Therapy is a biotechnology company developing first-in-class peptides as targeted therapies for severe diseases, with an initial focus on cancer. PEP-Therapy develops Cell Penetrating and Interfering Peptides (CP&IP) for the intracellular delivery of targeted therapies. These active compounds penetrate cells and block relevantintracellular protein-protein interactions, thus inhibiting key pathological mechanisms. | $1.4M / Seed / Apr 27, 2015 |
Co-Investors
About Fournier-Majoie
Fournier-Majoie Foundation is a non-profit organization whose mission is to identify, support and guide promising researchers.
Fournier-Majoie Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Bernard Majoie
President
|
|||
4 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Bernard Majoie invest in?
Bernard Majoie invests primarily in Biotechnology, Medical and Health Care startups, most often at Seed and Pre-Seed stage. Most of the 6 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Bernard Majoie's check size?
Bernard Majoie typically joins rounds of $1.3M–$2.7M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Bernard Majoie participates in.
When did Bernard Majoie last invest?
The most recent investment recorded for Bernard Majoie closed in Jul 2021. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
